Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Yasir S. Raouf"'
Autor:
Nabanita Nawar, Shazreh Bukhari, Ashley A. Adile, Yujin Suk, Pimyupa Manaswiyoungkul, Krimo Toutah, Olasunkanmi O. Olaoye, Yasir S. Raouf, Abootaleb Sedighi, Harsimran Kaur Garcha, Muhammad Murtaza Hassan, William Gwynne, Johan Israelian, Tudor B. Radu, Mulu Geletu, Ayah Abdeldayem, Justyna M. Gawel, Aaron D. Cabral, Chitra Venugopal, Elvin D. de Araujo, Sheila K. Singh, Patrick T. Gunning
Publikováno v:
Journal of Medicinal Chemistry. 65:3193-3217
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc016ee3578a633ee7c466b4bdc32cac
https://doi.org/10.1021/acs.jmedchem.1c01585
https://doi.org/10.1021/acs.jmedchem.1c01585
Autor:
Yasir S. Raouf, Patrick T. Gunning, Ayah Abdeldayem, Richard Moriggl, Stefan N. Constantinescu
Publikováno v:
Chemical Society reviews, Vol. 49, no. 9, p. 2617-2687 (2020)
Over the past decade, covalent kinase inhibitors (CKI) have seen a resurgence in drug discovery. Covalency affords a unique set of advantages as well as challenges relative to their non-covalent counterpart. After reversible protein target recognitio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdc5531c27037ef3efe873af44971648
https://doi.org/10.1039/c9cs00720b
https://doi.org/10.1039/c9cs00720b
Autor:
Nabanita, Nawar, Shazreh, Bukhari, Ashley A, Adile, Yujin, Suk, Pimyupa, Manaswiyoungkul, Krimo, Toutah, Olasunkanmi O, Olaoye, Yasir S, Raouf, Abootaleb, Sedighi, Harsimran Kaur, Garcha, Muhammad Murtaza, Hassan, William, Gwynne, Johan, Israelian, Tudor B, Radu, Mulu, Geletu, Ayah, Abdeldayem, Justyna M, Gawel, Aaron D, Cabral, Chitra, Venugopal, Elvin D, de Araujo, Sheila K, Singh, Patrick T, Gunning
Publikováno v:
Journal of medicinal chemistry. 65(4)
Histone deacetylase 6 (HDAC6) has been targeted in clinical studies for anticancer effects due to its role in oncogenic transformation and metastasis. Through a second-generation structure-activity relationship (SAR) study, the design, and biological
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ccaa9dc361e803b55be29c9580f2b35a
https://pubmed.ncbi.nlm.nih.gov/35119267
https://pubmed.ncbi.nlm.nih.gov/35119267
Autor:
Andrew E. Shouksmith, Abootaleb Sedighi, Yasir S. Raouf, Niyati Kachhiyapatel, Ayah Abdeldayem, Paris R. Watson, Krimo Toutah, Olasunkanmi O. Olaoye, David W. Christianson, Patrick T. Gunning, Shazreh Bukhari, Pimyupa Manaswiyoungkul, Justyna M. Gawel, Aaron D. Cabral, Johan Israelian, Muhammad Murtaza Hassan, Nabanita Nawar, Fettah Erdogan, Elvin D. de Araujo, Tudor B. Radu, Mulu Geletu
Publikováno v:
J Med Chem
Histone deacetylase 6 (HDAC6) is involved in multiple regulatory processes, ranging from cellular stress to intracellular transport. Inhibition of aberrant HDAC6 activity in several cancers and neurological diseases has been shown to be efficacious i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9badc9098e407d7f5ed776a4126d1106
https://pubmed.ncbi.nlm.nih.gov/33576627
https://pubmed.ncbi.nlm.nih.gov/33576627
Autor:
Patrick T. Gunning, Yasir S. Raouf, Muhammad Murtaza Hassan, Jana von Jan, Aleksandr Ianevski, Muzaffar N. Bhatti, Justyna M. Gawel, Mulu Geletu, Pimyupa Manaswiyoungkul, Nabanita Nawar, Elvin D. de Araujo, Helena Sorger, Olasunkanmi O. Olaoye, Tero Aittokallio, Oliver H. Krämer, Marco Herling, Sanna Timonen, Ayah Abdeldayem, Krimo Toutah, Tudor B. Radu, Richard Moriggl, Shazreh Bukhari, Johan Israelian, Heidi A. Neubauer, Satu Mustjoki, Andrew E. Shouksmith, Abootaleb Sedighi
Publikováno v:
Journal of Medicinal Chemistry
Epigenetic targeting has emerged as an efficacious therapy for hematological cancers. The rare and incurable T-cell prolymphocytic leukemia (T-PLL) is known for its aggressive clinical course. Current epigenetic agents such as histone deacetylase (HD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e3a89d15e76dd9bd052d4a50193efb2
http://hdl.handle.net/10852/93204
http://hdl.handle.net/10852/93204
Autor:
Muhammad Murtaza Hassan, Yasir S. Raouf, Pimyupa Manaswiyoungkul, Aaron D. Cabral, Abootaleb Sedighi, Rabia Altintas, Fettah Erdogan, Patrick T. Gunning, Giovanni Ganda, David W.J. Armstrong, Olasunkanmi O. Olaoye, Elvin D. de Araujo, Johan Israelian, Fabrizio Angeles, Nabanita Nawar
Publikováno v:
Journal of medicinal chemistry. 63(15)
Histone deacetylases (HDACs) are an attractive therapeutic target for a variety of human diseases. Currently, all four FDA-approved HDAC-targeting drugs are nonselective, pan-HDAC inhibitors, exhibiting adverse side effects at therapeutic doses. Alth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::456714751dd802b91d1d0aa5585e2945
https://pubmed.ncbi.nlm.nih.gov/32672458
https://pubmed.ncbi.nlm.nih.gov/32672458
Autor:
Abootaleb Sedighi, Yasir S. Raouf, Diana Sina, Krimo Toutah, Johan Israelian, Andrew E. Shouksmith, Patrick T. Gunning, Shazreh Bukhari, Elvin D. de Araujo, Olasunkanmi O. Olaoye, Aaron D. Cabral, Nabanita Nawar, Tudor B. Radu, Justyna M. Gawel, Pimyupa Manaswiyoungkul
Publikováno v:
European journal of medicinal chemistry. 201
Dysregulated Histone Deacetylase (HDAC) activity across multiple human pathologies have highlighted this family of epigenetic enzymes as critical druggable targets, amenable to small molecule intervention. While efficacious, current approaches using
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6f8e10ab2f4288fa6181dfde142909e
https://pubmed.ncbi.nlm.nih.gov/32615502
https://pubmed.ncbi.nlm.nih.gov/32615502
Autor:
Elvin D. de Araujo, Andrew E. Shouksmith, Abootaleb Sedighi, Aaron D. Cabral, Patrick T. Gunning, Pimyupa Manaswiyoungkul, Diana Sina, Shazreh Bukhari, Yasir S. Raouf, Justyna M. Gawel, Liying He, Alexandra E. Johns, Nabanita Nawar, Olasunkanmi O. Olaoye
Publikováno v:
ACS Med Chem Lett
[Image: see text] The HDAC inhibitor 4-tert-butyl-N-(4-(hydroxycarbamoyl)phenyl)benzamide (AES-350, 51) was identified as a promising preclinical candidate for the treatment of acute myeloid leukemia (AML), an aggressive malignancy with a meagre 24%
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8b6bfa2d897a97ac51dd37f2f9572b1
https://pubmed.ncbi.nlm.nih.gov/31938464
https://pubmed.ncbi.nlm.nih.gov/31938464
Autor:
Mulu Geletu, Angelika Berger-Becvar, Ashley A. Adile, William L. Heaton, Stephen F. Konieczny, Justyna M. Gawel, Patrick T. Gunning, Andrew E. Shouksmith, Melissa L. Fishel, Sheila K. Singh, Thomas O'Hare, Michael W. Deininger, H. Artee Luchman, David Bakhshinyan, Michelle Grimard, Chitra Venugopal, Yasir S. Raouf, Fenil Shah, Samuel Weiss, Elvin D. de Araujo
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive, incurable cancer with a 20% 1 year survival rate. While standard-of-care therapy can prolong life in a small fraction of cases, PDAC is inherently resistant to current treatments, and novel th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1efc7d1410f4a07409fa1893dcd093a1
https://europepmc.org/articles/PMC7190078/
https://europepmc.org/articles/PMC7190078/